Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.40 |
| ▸ | OXTR | P30559 | 2/20 | 0.32 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2516931 | 0.90 | SIRT6 (0.45) | SIRT6OXTRAVPR2SCN9AAVPR1A | |
| SCHEMBL2482296 | 0.90 | SIRT6 (0.45) | SIRT6OXTRAVPR2SCN9AAVPR1A | |
| SCHEMBL2480687 | 0.86 | SIRT6 (0.38) | SIRT6 | |
| SCHEMBL590269 | 0.77 | OXTR (0.44) | SIRT6OXTRAVPR2SCN9AAVPR1A | |
| SCHEMBL589821 | 0.76 | SIRT6 (0.37) | SIRT6 | |
| SCHEMBL589543 | 0.76 | SIRT6 (0.37) | SIRT6 | |
| SCHEMBL2133704 | 0.76 | SIRT6 (0.37) | SIRT6 | |
| SCHEMBL588733 | 0.70 | SIRT6 (0.47) | SIRT6 | |
| SCHEMBL30489397 | 0.69 | SIRT6 (0.51) | SIRT6 | |
| SCHEMBL28945656 | 0.68 | SIRT6 (0.46) | SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110250139-A1 | Modified Pyrazine Derivatives and Uses Thereof | MEDIBEACON, INC. | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250139-A1 | Modified Pyrazine Derivatives and Uses Thereof | GLS, GLS2, PLPBP | SIRT6 2338/4885OXTR 2580/4885AVPR2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.